Beyond Cholesterol
For decades, cardiovascular disease prevention focused almost exclusively on cholesterol levels. While LDL cholesterol remains an important risk factor, a growing body of evidence suggests that metabolic dysfunction — insulin resistance, chronic inflammation, and visceral adiposity — may be the more fundamental driver of atherosclerosis and heart disease.
The Heart and Stroke Foundation of Canada reports that 80% of premature heart disease and stroke is preventable through lifestyle modifications. Yet the traditional risk factor model misses many patients who go on to have cardiac events despite "normal" cholesterol levels.
The Insulin Resistance Connection
Research from the Montreal Heart Institute has demonstrated that insulin resistance is present in up to 50% of patients with coronary artery disease, even those without a diabetes diagnosis. Insulin resistance promotes atherogenic dyslipidemia (high triglycerides, low HDL, small dense LDL particles), endothelial dysfunction, and a pro-inflammatory state — all of which accelerate plaque formation.
Home Monitoring Matters
Simple home monitoring can provide early warning signs of metabolic-cardiovascular risk. Regular blood pressure checks, waist circumference measurements, and awareness of fasting blood sugar trends can help Canadians identify problems years before they become clinical emergencies.
An Integrated Approach
The future of cardiovascular prevention lies in addressing metabolic health holistically. GLP-1 receptor agonists have shown remarkable cardiovascular benefits beyond their metabolic effects. The SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide, even in patients without diabetes. This represents a paradigm shift in how we think about heart disease prevention.
